Biovest wins orphan drug status for cancer vax

Biovest International has announced that the FDA has granted orphan drug designation to BiovaxID, its personalized cancer vaccine, for a second lymphoma indication. "With promising clinical trials now complete in both follicular lymphoma and mantle cell lymphoma, we are preparing to seek regulatory approvals for BiovaxID in two separate indications," says Dr. Carlos Santos, Biovest's VP, product development & regulatory affairs. Release